Waiting for study results, physicians explore ways to optimize AMD treatment

Cimberle, Michela; Nale, Pat
February 2009
Ocular Surgery News;2/25/2009, Vol. 27 Issue 4, p1
Academic Journal
The article reports that many physicians are exploring ways to optimize the treatment for age-related macular degeneration (AMD) while waiting for the results of a trial comparing two leading anti-vascular endothelial growth factor (VEGF) agents in the treatment of AMD. The clinical trial compares Lucentis, which has been approved by the U.S. Food and Drug Administration (FDA) to treat wet AMD, against Avastin, which is used off-label for wet AMD.


Related Articles

  • POINT/COUNTER.  // Ocular Surgery News;2/25/2009, Vol. 27 Issue 4, p11 

    The article presents opposing views on ongoing CATT studies regarding the treatment for wet age-related macular degeneration (AMD). Physician Sophie J. Bakri expects the trial results to tell if Avastin is non-inferior to Lucentis when given on a monthly basis, and if each drug is better given...

  • Inside the AMD Trials What to Look for. Thomas, Edger L. // Review of Ophthalmology;Dec2005, Vol. 12 Issue 12, Special section p2 

    The article presents information on age-related macular degeneration (AMD) trials. AMD is a very complex pathobiologic process which involves angiogenic, cellular, structural and cicatical factors. The earliest treatment for curing AMD is photocoagulation. Recently, diabetic retinopathy became a...

  • Macugen.  // Pharmaceutical Representative;Mar2005, Vol. 35 Issue 3, p13 

    Reports on the finding that the anti-angiogenic drug Macugen (pegaptanib sodium Injection), marketed by Eyetech Pharmaceuticals Inc. and Pfizer Inc., may preserve vision in patients with neovascular ("wet") age-related macular degeneration, according to combined results of two prospective,...

  • Lucentis Granted Priority Food and Drug Review.  // Review of Ophthalmology;Apr2006 Part 1 Of 2, Vol. 13 Issue 4, p12 

    The article reports that the U.S. Food and Drug Administration (FDA) has accepted Genentech Inc.'s Biologics Licence Application for the use of Lucentis in the treatment of neovascular age-related macular degeneration (AMD). Genentech was given a six-month Priority Review, specified for its...

  • Phase III study eyes intravitreal therapy for exudative AMD. Guttman, Cheryl; Heier, Jeffrey S. // Ophthalmology Times;7/1/2004, Vol. 29 Issue 13, p40 

    Focuses on the conduction of two phase II clinical studies to evaluate intravitreal ranibizumab monotherapy for the treatment of exudative age-related macular degeneration in the U.S. Use of the drug to improve vision; Common adverse events from the medication; Investigation of safety,...

  • AART to assess use of anecortave acetate in preventing progression to wet AMD. Slakter, Jason S. // Ophthalmology Times;3/1/2007, Vol. 32 Issue 5, p30 

    The article presents a clinical trial which examines the utilization C-20-60 Anecortave Acetate Risk Reduction Trial (AART) in determining the role of anecortave acetate in the prevention of age-related macular degeneration (AMD). Preclinical studies revealed that the drug is capable of reducing...

  • AMD research takes aim at choroidal neovascularization. Lim, Jennifer Irene // Ophthalmology Times;8/15/2005, Vol. 30 Issue 16, p11 

    Reports on research developments related to age-related macular degeneration (AMD). Drugs for the treatment of choroidal neovascularization developed through translational research; Advances in photodynamic therapy; Clinical trials that show promise in managing AMD. INSET: Take-Home Message.

  • Anti-VEGF AMD drug yields visual benefit. Miller, Joan W. // Ophthalmology Times;8/15/2005, Vol. 30 Issue 16, p1 

    Reports that intravitreal injection with the anti-vascular endothelial growth factor antibody, ranibizumab, has been associated with impressive results in the treatment of minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration, according to the...

  • Genaera's AMD trials earn FDA attention.  // Ophthalmology Times;8/15/2005, Vol. 30 Issue 16, p8 

    Reports that Genaera Corp. has won a Special Protocol Assessment (SPA) designation from the United States Food and Drug Administration for the design of two global registration phase III clinical trials evaluating squalamine lactate for the treatment of choroidal neovascularization associated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics